Výsledky vyhledávání - "Joanne Halsey"

A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer

Autor: Erich J. Schwartz, Meghan Ramsey, George A. Fisher, Robert V. Rouse, Timothy Kuo, Branimir I. Sikic, Cheryl D. Cho, Joanne Halsey

Publikováno v: Clinical Cancer Research. 14:7074-7079

Purpose: We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer. Experimental Design: Eligible patients had stage IV colorectal adenocarcinom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a682cef41b13e4bef90fea094a47c9e7
https://doi.org/10.1158/1078-0432.ccr-08-1014

Zobrazit plný text záznamu

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer

Autor: Ranjana H. Advani, Branimir I. Sikic, Bert L. Lum, Joanne Halsey, George A. Fisher, T. Jesse Kwoh, Richard S. Geary, F. Andrew Dorr, Jon T. Holmlund

Publikováno v: Investigational New Drugs. 23:467-477

Purpose: A phase I study was performed to determine the maximum tolerated dose (MTD), safety profile and pharmacology of aprinocarsen (ISIS 3521), an antisense oligonucleotide to protein kinase C-α, in patients with refractory solid tumors. Experime

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d962f8056256f26cfb9c01f617e8d5e4
https://doi.org/10.1007/s10637-005-2906-0

Zobrazit plný text záznamu

Phase II Study of Gefitinib, Fluorouracil, Leucovorin, and Oxaliplatin Therapy in Previously Treated Patients With Metastatic Colorectal Cancer

Autor: Joanne Halsey, Heather A. Wakelee, Ranjana H. Advani, Timothy Kuo, Branimir I. Sikic, George A. Fisher, Cheryl D. Cho, James M. Ford

Publikováno v: Journal of Clinical Oncology. 23:5613-5619

Purpose To investigate the gefitinib, fluorouracil (FU), leucovorin, and oxaliplatin regimen (IFOX) in previously treated patients with metastatic colorectal cancer. Patients and Methods Eligible patients had stage IV colorectal adenocarcinoma and ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c613530ad8b61c33da10759324962d
https://doi.org/10.1200/jco.2005.08.359

Zobrazit plný text záznamu

Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies

Autor: Joanne Halsey, Branimir I. Sikic, Cheryl D. Cho, George A. Fisher

Publikováno v: Investigational New Drugs. 24:117-123

Purpose: Aphase 1 study of gefitinib in combination with oxaliplatin, 5-fluorouracil and leucovorin (IFOX)was conducted to evaluate the safety and feasibility of this regimen. Patients and Methods: Patients with advanced solid malignancies were treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c038d8e361bf7ed2744eda3a7e669c8f
https://doi.org/10.1007/s10637-006-2032-7

Zobrazit plný text záznamu

Clinical trials of modulation of multidrug resistance pharmacokinetic and pharmacodynamic considerations

Autor: Branimir I. Sikic, Sonja Kaubisch, N A Brophy, Kent M. Adler, George A. Fisher, Bert L. Lum, Anne M. Yahanda, Joanne Halsey

Publikováno v: Cancer. 72:3502-3514

A growing body of evidence indicates that expression of the mdr1 gene, which encodes the multidrug transporter, P-glycoprotein, contributes to chemotherapeutic resistance of human cancers. Expression of this protein in normal tissues such as the bili

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db262dd3d50991e687945e71b57c5cd0
https://doi.org/10.1002/1097-0142(19931201)72:11+<3502::aid-cncr2820721618>3.0.co

Zobrazit plný text záznamu

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

Autor: Lyle Jew, Mohamed N. Ehsan, N A Brophy, Sonia Kaubisch, Michael P. Gosland, Bert L. Lum, Joanne Halsey, Kent M. Adler, Anne M. Yahanda, Branimir I. Sikic

Publikováno v: Journal of Clinical Oncology. 10:1635-1642

PURPOSE To determine the effects of high-dose cyclosporine (CsA) infusion on the pharmacokinetics of etoposide in patients with cancer. PATIENTS AND METHODS Sixteen patients were administered 20 paired courses of etoposide and CsA/etoposide. Etoposid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcf6889f84af78d5323958ef2d55a5c2
https://doi.org/10.1200/jco.1992.10.10.1635

Zobrazit plný text záznamu

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance

Autor: N A Brophy, Bert L. Lum, Joanne Halsey, Anne M. Yahanda, George A. Fisher, Michael P. Gosland, K M Alder, R I Hardy, Branimir I. Sikic

Publikováno v: Journal of Clinical Oncology. 10:1624-1634

PURPOSE To determine the maximum-tolerated dose (MTD) of cyclosporine (CsA) infusion administered with etoposide for 3 days in patients with cancer. PATIENTS AND METHODS Of the 72 registered patients, 26 were treated initially with CsA and etoposide.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b59f4ffe516b292c20a91441899768d
https://doi.org/10.1200/jco.1992.10.10.1624

Zobrazit plný text záznamu

The use of probenecid as a chemoprotector against cisplatin nephrotoxicity

Autor: Bert L. Lum, Charlotte Jacobs, Joanne Halsey, Michael P. Gosland, Sonja Kaubisch, C. Norman Coleman, Branimir I. Sikic

Publikováno v: Cancer. 67:1518-1524

Probenecid inhibits cisplatin (CP) secretion in humans and protects against CP-induced nephrotoxicity in rats. The authors conducted a Phase I trial of escalating doses of CP using probenecid as a chemoprotector. Fifty-four courses of CP at doses ran

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ba51eb1acc63d5efeddb5e69adf9b501
https://doi.org/10.1002/1097-0142(19910315)67:6<1518::aid-cncr2820670610>3.0.co

Zobrazit plný text záznamu

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma

Autor: George A. Fisher, Harry J. Long, Prema P. Peethambaram, Bert L. Lum, Jon T. Holmlund, Joanne Halsey, Andrew Dorr, Ranjana H. Advani, Branimir I. Sikic, Lynn C. Hartmann

Publikováno v: Cancer. 100(2)

BACKGROUND It has been postulated that protein kinase C α (PKC-α) plays a pivotal role in signal transduction in tumor cancer cells. Aprinocarsen, a 20-base antisense oligonucleotide, has shown ability to inhibit PKC-α protein expression and inhib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13f42c4784bf198043dc3e32ddc64919
https://pubmed.ncbi.nlm.nih.gov/14716767

Zobrazit plný text záznamu

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

Autor: George A. Fisher, Gang Chen, Bert L. Lum, Lidija Beketić-Orešković, Branimir I. Sikic, Joanne Halsey

Publikováno v: Cancer chemotherapy and pharmacology.

Intrinsic and acquired multidrug resistance (MDR) in many human cancers may be due to expression of the multidrug transporter P-glycoprotein (Pgp), which is encoded by the mdr1 gene. There is substantial evidence that Pgp is expressed both as an acqu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4741e9ca76c58f4e3c46c514cea5fdce
https://pubmed.ncbi.nlm.nih.gov/9272128

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání